{"created":"2023-07-27T06:51:15.288240+00:00","id":44607,"links":{},"metadata":{"_buckets":{"deposit":"fad42847-234e-493c-baed-e56868f6ad0a"},"_deposit":{"created_by":18,"id":"44607","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"44607"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00044607","sets":["2812:2813:2820"]},"author_link":["76695","284"],"item_9_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-05-28","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"6p.","bibliographicVolumeNumber":"2011-2013","bibliographic_titles":[{"bibliographic_title":"平成25(2013)年度 科学研究費補助金 基盤研究(C) 研究成果報告書"},{"bibliographic_title":"2013 Fiscal Year Final Research Report","bibliographic_titleLang":"en"}]}]},"item_9_creator_33":{"attribute_name":"著者別表示","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{}],"nameIdentifiers":[{},{}]}]},"item_9_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"肺癌の治療では個別化療法が進歩している。cMetは増殖因子受容体で、EGFRチロシンキナーゼ阻害剤に対する薬剤耐性因子として重要である。DNAトポイソメラーゼI(TopoI)はDNA複製に必要で、イリノテカンの標的酵素である。我々はこの二つの関連に注目している。我々は肺癌細胞株を用いてｃMetがTopoIの発現を調整しており、TopoI阻害剤であるｲﾘﾉﾃｶﾝの感受性を規定することを示した。さらに肺癌症例の病理検体でMet蛋白とTopoIが相関していることを示し、さらにcMet蛋白が化学療法受けた症例の予後因子であることを証明した。\n本研究は肺癌治療の個別化療法の進歩に有意義と考えられる。","subitem_description_type":"Abstract"},{"subitem_description":"Personalized therapy progresses in the treatment of the lung cancer. cMet is important as a drug-resistant factor for the EGFR tyrosine kinase inhibitor. DNA topoisomerase I (TopoI) is necessary for replication of DNA and is a target enzyme of irinotecan. We focused on the relation between these two protein . cMet up-regulate expression of TopoI in lung cancer cell lines, and we showed that it prescribed sensitivity of irinotecan, a TopoI inhibitor. Furthermore, We showed that TopoI correlated to Met protein in the tumor sample of the lung cancer patients and that cMet protein was the prognostic factor.\nAs for this study, it is significant for progress of the personalized therapy for lung cancer treatment.","subitem_description_type":"Abstract"}]},"item_9_description_22":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号:23501306, 研究期間(年度):2011-2013","subitem_description_type":"Other"},{"subitem_description":"出典：「肺癌におけるcMetとTopoisomerase Iの関連」研究成果報告書　課題番号23501306\n（KAKEN：科学研究費助成事業データベース（国立情報学研究所））\n（https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23501306/23501306seika/)を加工して作成","subitem_description_type":"Other"}]},"item_9_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系","subitem_description_type":"Other"}]},"item_9_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.24517/00050948","subitem_identifier_reg_type":"JaLC"}]},"item_9_publisher_17":{"attribute_name":"公開者","attribute_value_mlt":[{"subitem_publisher":"金沢大学医薬保健研究域医学系"}]},"item_9_relation_28":{"attribute_name":"関連URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/search/?qm=30272967"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/search/?qm=30272967","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23501306/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23501306/","subitem_relation_type_select":"URI"}},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23501306/23501306seika/"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23501306/23501306seika/","subitem_relation_type_select":"URI"}}]},"item_9_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-06-04"}],"displaytype":"detail","filename":"ME-PR-KASAHARA-K-kaken 2014-6p.pdf","filesize":[{"value":"384.4 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"ME-PR-KASAHARA-K-kaken 2014-6p.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/44607/files/ME-PR-KASAHARA-K-kaken 2014-6p.pdf"},"version_id":"3f1e2682-162c-4bda-a912-53a2ebe426de"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"肺癌におけるcMetとTopoisomerase Iの関連","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"肺癌におけるcMetとTopoisomerase Iの関連"},{"subitem_title":"Relation cMet and Topoisomerase I in lung cancer","subitem_title_language":"en"}]},"item_type_id":"9","owner":"18","path":["2820"],"pubdate":{"attribute_name":"公開日","attribute_value":"2018-06-04"},"publish_date":"2018-06-04","publish_status":"0","recid":"44607","relation_version_is_last":true,"title":["肺癌におけるcMetとTopoisomerase Iの関連"],"weko_creator_id":"18","weko_shared_id":-1},"updated":"2023-07-27T09:19:37.204644+00:00"}